Skip Ribbon Commands
Skip to main content
Sign In

* Please note that certain products may not be available in all countries

TRINITY Evolution®






TRINITY Evolution is an allograft comprised of cancellous bone with viable osteogenic ​and osteoprogenitor cells retained within the matrix and a demineralized cortical bone component. TRINITY Evolution offers an ideal alternative to autograft and other bone grafting options.

Adult mesenchymal stem cells (MSCs) are multipotential and capable of responding to their environment to differentiate into a variety of cells as needed. When implanted in patients, MSCs and osteoprogenitor cells do not stimulate an immune response.1

TRINITY Evolution is processed by the Musculoskeletal Transplant Foundation (MTF Biologics), a nonprofit organization dedicated to providing quality tissue. Every step, from donor screening to cryopreservation and pre-release testing, has been designed to maximize cell health and ensure patient safety.

Physician Benefits

Ensuring quality at every step:

  • MTF Biologics is committed to excellence in tissue quality
  • Cell health is preserved through donor selection, careful processing and vapor phase liquid nitrogen storage​

TRINITY Evolution supplies the three essential components for robust bone formation:

  • Osteoconductive scaffold
  • Verified osteoinductive potential
  • A reliable number of viable cells retained within the bone matrix2 ​


  1. ​Le Blanc, K, et al. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol, 2​003. 31(10): p. 890.6 and Neimeyer, P., et al., Mesenchymal stem cell-based HLA-independent cell therapy for tissue engineering of bone and cartilage. Curr Stem Cell Res Ther, 2006. 1(1): p. 21-7.​

  2. Data on file with MTF


TRINITY Evolution is an allograft intended for the treatment of musculoskeletal defects.

Clinical References

Clinical References​

  •  Rush S. Mesenchymal Stem Cell Allografting in Foot and Ankle Surgery. Foot & Ankle Specialist June 2010 Vol. 3(3):140-147. 
  • D'Ippolito G et al: Age-Related Osteogenic Potential of Mesenchymal Stromal Stem Cells from Human Vertebral Bone Marrow. Journal of Bone and Mineral Research 1999 Jul; Vol. 14(7):1115-22. 

Non-Clinical Refe​​rences​

  • Pountos I, Giannoudis P: Biology of Mesenchymal Stem Cells. Injury 2005 Nov; Vol. 36 Suppl. 3:S8-S12.
  • Barry FP, Murphy JM: Mesenchymal Stem Cells: Clinical Applications and Biological Characterization. International Journal of Biochemistry and Cell Biology 2004 Apr; Vol. 36(4):568-84.
  • Bonab M et al: Aging of Mesenchymal Stem Cell in Vitro. BMC Cell Biology 2006 Mar 10; Vol. 7:14. 
  • ​Sethe S et al: Aging of Mesenchymal Stem Cells. Ageing Research Reviews 2006 Feb; Vol. 5(1):91-116. 
  • Stolzing A et al: Age-Related Changes in Human Bone Marrow-Derived Mesenchymal Stem Cells: Consequences for Cell Therapies. Mechanisms of Ageing and Development 2008 Mar; Vol. 129(3):163-73. 
  • Le Blanc K et al: HLA Expression and Immunologic Properties of Differentiated and Undifferentiated Mesenchymal Stem Cells. Experimental Hematology 2003 Oct; Vol. 31(10):890-6. 
  • Ryan JM et al: Mesenchymal Stem Cells Avoid Allogeneic Rejection. Journal of Inflammation (London) 2005 Jul 26; Vol. 2:8. 
  • Mazur P: Freezing of Living Cells: Mechanisms and Implications. American Journal of Physiology 1984 Sep; Vol. 2 47(3 Pt 1):C125-42.

Instructions for Use